LANSING, Mich., July 15, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, today announced that it is scheduled to start commercial production of Monster Silk™.
The first phase, scheduled to begin within the next three weeks, will be focused on establishing commercial scale production capacity. "We have been laying the ground work for commercial production over the last six months with our pilot production program," said Company CEO and founder, Kim K Thompson. "We have moved cautiously and prudently in testing our methods and procedures. It's now time to convert the pilot program to commercial production."
The launch of commercial production follows on the heels of the Company's pilot production program which has been running since January.
"The successful scale-up to commercial production is a significant milestone for any company," continued Thompson, "and, considering the importance we place on Monster Silk™, I have to agree that this is a momentous step for Kraig. It is especially exciting because we are creating what we believe will be the world's first commercial scale production of recombinant spider silk."
While the Company is creating this production capacity, it is in discussions with one or more other countries about further expanding and diversifying its production capacity for Monster Silk™.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc